Immutep Ltd
ASX:IMM
Immutep Ltd
ASX:IMM
Price:
0.485 AUD
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
The Relative Value of one
IMM
stock under the Base Case scenario is
2.912
AUD.
Compared to the current market price of 0.485 AUD,
Immutep Ltd
is
Undervalued by 83%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
IMM
Relative Value
Base Case
2.912
AUD
Undervaluation 83%
Valuation Multiples
Multiples Across Competitors
IMM Competitors Multiples
Immutep Ltd Competitors
Immutep Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| AU |
|
Immutep Ltd
ASX:IMM
|
576.6m AUD | 2 246.8 | -14.2 | -10.1 | -10.1 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 5.2 | 58.8 | 12.8 | 19.5 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
163.3B USD | 5.5 | 43.4 | 18.4 | 30.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.1B USD | 8.1 | 27.5 | 22.2 | 24.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.1B USD | 11.1 | 30.3 | 24.3 | 25.4 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.1B USD | 3 | 167.8 | 6.7 | 8.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.6B USD | 9.1 | -7.8 | -8.5 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.3 | 46 | 63.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
